Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment

被引：0
|
作者：
Post, F. [1 ]
Andrade-Villanueva, J. [2 ]
Fisher, M. [3 ]
Winston, J. [4 ]
Liu, Y. [5 ]
Zhong, L. [5 ]
Cheng, A. [5 ]
Rhee, M. [5 ]
Szwarcberg, J. [5 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Hosp Civil Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
[3] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England
[4] Mt Sinai Sch Med, New York, NY USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2014年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [21] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects
    Sax, P.
    DeJesus, E.
    Mills, A.
    Zolopa, A.
    Cohen, C.
    Wohl, D.
    Gallant, J.
    Bosse, M.
    White, K.
    Liu, C.
    Plummer, A.
    Kearney, B.
    Quirk, E.
    Cheng, A.
    HIV MEDICINE, 2012, 13 : 9 - 9
  • [22] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
    Nozza, Silvia
    Poli, Andrea
    Ripa, Marco
    Galli, Laura
    Chiappetta, Stefania
    Spagnuolo, Vincenzo
    Rovelli, Cristina
    Lazzarin, Adriano
    Castagna, Antonella
    Tambussi, Giuseppe
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (02) : 632 - 633
  • [23] Hepatic safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV/HCV co-infected subjects in the STRATEGY switch trials
    Rashbaum, B.
    Lucasti, C.
    Mounzer, K.
    Melbourne, K.
    Kwon, P.
    Piontkowsky, D.
    ANTIVIRAL THERAPY, 2014, 19 : A44 - A45
  • [24] Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients
    Huang, Yu-Shan
    Cheng, Chien-Yu
    Liou, Bo-Huang
    Lu, Po-Liang
    Cheng, Shu-Hsing
    Lee, Yuan-Ti
    Liu, Chun-Eng
    Sun, Hsin-Yun
    Yang, Chia-Jui
    Tang, Hung-Jen
    Lin, Shih-Ping
    Ho, Mao-Wang
    Huang, Sung-Hsi
    Tsai, Hung-Chin
    Lee, Chen-Hsiang
    Hung, Chien-Ching
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : 473 - 481
  • [25] Single-tablet regimen with elvitegravir, cobicistat, emtricitabine and tenofovir for the treatment of early HIV infection
    Teira, Ramon
    Galindo, Maria
    Montero, Marta
    Portilla, Raquel
    Ferrer, Ana
    Martinez, Elisa
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [26] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideLack of efficacy: case report
    Reactions Weekly, 2021, 1867 (1) : 137 - 137
  • [27] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideAllergic pruritus: case report
    Reactions Weekly, 2018, 1703 (1) : 86 - 86
  • [28] Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamideAllergic pruritus: case report
    Reactions Weekly, 2018, 1714 (1) : 123 - 123
  • [29] Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamideTrigeminal autonomic cephalgia: case report
    Reactions Weekly, 2018, 1710 (1) : 103 - 103
  • [30] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight
    Max, Blake
    DeMarais, Patricia
    INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (01) : 92 - 95
12345